# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Florence Griffith Joyner (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML033-SYN
- Date: 2026-07-21
- Fictional facility: St. Posthumous Health Center
- Fictional author: Celeste Vanterpool, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Five weeks after lesionectomy: recovery, seizure control, and return to training. **S**

## History of present illness

Ms. Griffith Joyner returns five weeks after a left frontal craniotomy with complete removal of the cavernous malformation and its hemosiderin rim. She went home on the third day. The MRI the day after surgery showed complete resection. She needed acetaminophen for about two weeks and nothing since. The incision has healed. She has had no seizure, spell, headache, or change in smell, mood or concentration. She has walked daily since the second week and began easy running last week without symptoms. She takes levetiracetam twice a day; the irritability has gone. She has not driven. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Surgery | Complete lesionectomy; home on day 3; MRI: complete resection |
| Seizures | None |
| Training | Walking, then easy running for a week |
| Levetiracetam | Taken twice daily; irritability resolved |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy back to normal |
| Neurological | Negative | No seizures, spells, headache, numbness or change in smell |
| Integumentary | Negative | Scalp incision healed |
| Psychiatric | Negative | Mood good; PHQ-9 4; no thoughts of self-harm |

4 systems reviewed. **S**

## Current medications

- Levetiracetam 500 mg oral tablet, one tablet by mouth twice daily **S**
- Folic acid 0.4 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 108/68 mmHg; pulse 62 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 60.1 kg; BMI 20.8 kg/m². All vital signs are synthetic.

PHQ-9: 4. All results are synthetic.

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 60.1 kg; blood pressure 108/68, pulse 62 |
| Head | Left frontal incision healed behind the hairline without swelling or tenderness |
| Neurological | Alert and oriented; smell intact; cranial nerves, strength, coordination and gait normal |
| Psychiatric | Bright and engaged |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Focal epilepsy with structural cause, after complete lesionectomy** (G40.209). Seizure-free since the flight, three and a half months ago, and since surgery. After complete removal of a cavernous malformation with its hemosiderin rim, most patients become seizure-free; levetiracetam continues for at least two years before any taper is considered. **S**
   - Continue levetiracetam 500 mg twice daily and folic acid.
   - Graded return to training: running now, sprint sessions from six to eight weeks after surgery, full training by three to four months; no heavy lifting until eight weeks.
   - Swim only with a companion; keep the detection watch.
2. **Cerebral cavernous malformation, completely excised** (Q28.3). Pathology confirmed a cavernous malformation; postoperative MRI shows complete resection. No further imaging is needed unless new symptoms appear; resolved. **S**
   - Problem resolved.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Postoperative MRI | After resection of a cavernous malformation | Up to date | Day after surgery: complete resection, no hemorrhage |
| Examination | Wound and neurological examination after craniotomy | After surgery | Completed today | Healed; examination normal |
| Self-management | Seizure diary and adherence | Each visit | Completed today | No seizure; every dose taken |
| Survey | Mood and behavior on levetiracetam (PHQ-9) | Before starting and at each visit | Completed today | PHQ-9 4; irritability resolved |
| Self-management | Graded return to training | After surgery | Completed today | Written plan agreed with the neurosurgeon's limits |
| Self-management | Driving restriction and the California physician report | From the first seizure until cleared | Up to date | Not driving; review at six months |
| Self-management | Nocturnal seizure detection | When seizures may occur in sleep | Completed today | Watch worn nightly; no alerts |
| Medication safety | Folic acid and contraception | Each visit | Completed today | Folic acid daily; no pregnancy planned |

## Goal progress

- EEG and MRI with susceptibility-weighted imaging within one week, and an epilepsy consultation within two weeks. Outcome by 2026-05-05: EEG in two days, MRI in six, consultation at two weeks. **S**
- No further seizures on an antiseizure medication she tolerates. In progress; target 2026-10-20. **S**
- Neurosurgical evaluation of the cavernous malformation and a shared decision about lesionectomy within two months. Outcome by 2026-07-21: Seen by neurosurgery at three weeks; complete lesionectomy at eight weeks. **S**
- Safety plan in place: no driving until cleared, water and height safety, SUDEP discussion, and a nocturnal seizure detection plan. Outcome by 2026-05-27: Driving stopped and reported as California requires; SUDEP discussed (one visit late, recorded as a deviation); detection watch in use. **S**
- Graded return to full sprint training within four months of surgery. In progress; target 2026-10-20. **S**

## Guideline basis

- Krumholz A, et al. Evidence-based guideline: Management of an unprovoked first seizure in adults. Neurology 2015;84(16):1705-1713 (PMID 25901057) (2015), American Academy of Neurology and American Epilepsy Society
- Akers A, et al. Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. Neurosurgery 2017;80(5):665-680 (PMID 28387823) (2017), Angioma Alliance (Neurosurgery)
- Pack AM, et al. Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication: Practice Guideline From the AAN, AES, and SMFM. Neurology 2024;102(11):e209279 (PMID 38748979) (2024), American Academy of Neurology, American Epilepsy Society and Society for Maternal-Fetal Medicine
- Beniczky S, et al. Automated seizure detection using wearable devices: A clinical practice guideline of the International League Against Epilepsy and the International Federation of Clinical Neurophysiology. Epilepsia 2021;62(3):632-646 (PMID 33666944) (2021), International League Against Epilepsy and International Federation of Clinical Neurophysiology
- Governor's message returning Senate Bill 357 without signature (physician reporting of disorders characterized by lapses of consciousness remains mandatory under Health and Safety Code section 103900) (2024), Office of the Governor of California
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Preventive visit next month. Six-month epilepsy review in October with the driving review. Call at once for any seizure, severe headache or new neurological symptom. **S**
- Next scheduled visit 2026-08-25: periodic adult preventive visit. **S**
